[go: up one dir, main page]

PE20141682A1 - Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio - Google Patents

Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio

Info

Publication number
PE20141682A1
PE20141682A1 PE2014000605A PE2014000605A PE20141682A1 PE 20141682 A1 PE20141682 A1 PE 20141682A1 PE 2014000605 A PE2014000605 A PE 2014000605A PE 2014000605 A PE2014000605 A PE 2014000605A PE 20141682 A1 PE20141682 A1 PE 20141682A1
Authority
PE
Peru
Prior art keywords
phenylimidazole
sodium channel
derivatives useful
channel modulators
ethylamine derivatives
Prior art date
Application number
PE2014000605A
Other languages
English (en)
Inventor
Sharanjeet Kaur Bagal
Mark Ian Kemp
Duncan Charles Miller
Yoshihisa Murata
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141682(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PE20141682A1 publication Critical patent/PE20141682A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) O UN TAUTOMERO DEL MISMO, DONDE: R1 Y R2, JUNTO CON EL CARBONO AL CUAL SE UNEN, FORMAN UN ANILLO DE 4 A 7 MIEMBROS; R3 ES H, CICLOPROPILO, -CH2OCH3, ENTRE OTROS; R4 ES -CF3, -OCF3, -OCHF2, ENTRE OTROS; R5 ES H, -CH3. SON COMPUESTOS PREFERIDOS 3-({4-[4-(TRIFLUOROMETOXI) FENIL]-1H-IMIDAZOL-2-IL}METIL)TETRAHIDRO-2H-PIRAN-3-AMINA, 3-{[4-(4-CLORO-3-METILFENIL)-1H-IMIDAZOL-2-IL]METIL}OXETAN-3-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DEL DOLOR.
PE2014000605A 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio PE20141682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551628P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
PE20141682A1 true PE20141682A1 (es) 2014-11-14

Family

ID=47278356

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000605A PE20141682A1 (es) 2011-10-26 2012-10-15 Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio

Country Status (28)

Country Link
US (1) US9079878B2 (es)
EP (1) EP2771335A2 (es)
JP (1) JP5946538B2 (es)
KR (1) KR101586966B1 (es)
CN (1) CN103906746B (es)
AP (1) AP2014007579A0 (es)
AU (1) AU2012328034B2 (es)
BR (1) BR112014009102A2 (es)
CA (1) CA2850925C (es)
CL (1) CL2014000956A1 (es)
CO (1) CO6940427A2 (es)
CR (1) CR20140185A (es)
CU (1) CU20140046A7 (es)
DO (1) DOP2014000085A (es)
EA (1) EA023375B1 (es)
EC (1) ECSP14013324A (es)
GT (1) GT201400079A (es)
IL (1) IL232267A (es)
MD (1) MD20140037A2 (es)
MX (1) MX337469B (es)
NI (1) NI201400031A (es)
PE (1) PE20141682A1 (es)
PH (1) PH12014500919A1 (es)
SG (1) SG11201401032YA (es)
TN (1) TN2014000147A1 (es)
UA (1) UA109220C2 (es)
WO (1) WO2013061205A2 (es)
ZA (1) ZA201402281B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607941C2 (ru) * 2011-09-14 2017-01-11 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Способы и системы для получения бороновых кислот и их промежуточных соединений
SG11201604477SA (en) 2013-12-13 2016-07-28 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
KR102192572B1 (ko) 2014-06-09 2020-12-18 삼성전자주식회사 광원 모듈의 불량 검사방법, 광원 모듈의 제조 방법 및 광원 모듈 검사장치
CN107206015A (zh) 2014-10-24 2017-09-26 阿维塔斯有限公司 透细胞质膜的传递
CA2977367A1 (en) 2015-02-19 2016-08-25 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
AU2016380836A1 (en) 2015-12-30 2018-07-12 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
EP3481857A1 (en) 2016-07-06 2019-05-15 Crispr Therapeutics AG Materials and methods for treatment of pain related disorders
JP7305534B2 (ja) * 2016-07-06 2023-07-10 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛関連障害を処置するための物質及び方法
AU2018271110A1 (en) 2017-05-16 2019-12-05 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
WO2019014352A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
CA3091012A1 (en) 2018-02-12 2019-08-15 Vertex Pharmaceuticals Incorporated A method of treating pain
EA202191177A1 (ru) 2018-11-02 2021-07-28 Мерк Шарп И Доум Корп. 2-амино-n-гетероарилникотинамиды в качестве ингибиторов nav1.8
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
UA130303C2 (uk) 2019-12-06 2026-01-14 Вертекс Фармасьютикалз Інкорпорейтед Заміщені тетрагідрофурани як модулятори натрієвих каналів
AU2022284952A1 (en) 2021-06-04 2023-12-14 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
MX2023014378A (es) 2021-06-04 2023-12-15 Vertex Pharma N-(hidroxialquil(hetero)aril)tetrahidrofurano carboxamidas como moduladores de canales de sodio.
AU2022283934A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
AU2022286438A1 (en) 2021-06-04 2023-11-30 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256842A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
KR20250005373A (ko) 2022-04-22 2025-01-09 버텍스 파마슈티칼스 인코포레이티드 통증 치료를 위한 헤테로아릴 화합물
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN119522214A (zh) 2022-04-22 2025-02-25 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
IL316433A (en) 2022-04-25 2024-12-01 Siteone Therapeutics Inc Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain
CN115656380B (zh) * 2022-11-09 2025-04-01 武汉海特生物创新医药研究有限公司 一种mtv对映异构体的hplc-uv检测方法
AU2023391870A1 (en) 2022-12-06 2025-06-05 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
TW202523313A (zh) 2023-10-23 2025-06-16 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain
WO2025160286A1 (en) 2024-01-24 2025-07-31 Siteone Therapeutics, Inc. 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
WO2025231324A1 (en) * 2024-05-02 2025-11-06 Genep Inc. Imidazole compounds and their use as sodium channel inhibitors
US20260001877A1 (en) 2024-06-28 2026-01-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2026013449A2 (en) 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US7291641B2 (en) 1999-10-11 2007-11-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
TWI292316B (en) * 1999-10-11 2008-01-11 Sod Conseils Rech Applic Pharmaceutical composition of thiazole derivatives intended to inhibit mao and/or lipidic peroxidation and/or to act as modulators of sodium channels and the use thereof
US7112366B2 (en) 2001-01-05 2006-09-26 The Ohio State University Chemical monolayer and micro-electronic junctions and devices containing same
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
FR2842808B1 (fr) * 2002-07-25 2004-09-10 Sod Conseils Rech Applic Nouveaux derives d'arylimidazoles, leur preparation et leurs applications therapeutiques
US7456164B2 (en) * 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
SI1747210T1 (sl) * 2004-05-07 2010-09-30 Warner Lambert Co ali monosubstituirani fenolin in tiofenolni derivati uporabni kot ligandi H
EP2371954A1 (en) * 2004-10-27 2011-10-05 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of NAv1.8
SI1963280T1 (sl) 2005-12-22 2016-02-29 Newron Pharmaceuticals S.P.A. 2-feniletilamino derivati kot modulatorji kalcijevih in/ali natrijevih kanalčkov
RS20090154A (sr) 2006-10-18 2010-10-31 Pfizer Products Inc. Jedinjenja biaril etra uree
ES2340640T3 (es) 2007-03-23 2010-06-07 Icagen, Inc. Inhibidores de canales de iones.
GEP20125379B (en) 2007-05-03 2012-01-10 Pfizer Ltd 2 -pyridine carboxamide derivatives as sodium channel modulators
US20100227872A1 (en) * 2007-05-03 2010-09-09 Mark Ian Kemp Pyrazine derivatives
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors

Also Published As

Publication number Publication date
WO2013061205A3 (en) 2013-06-27
EP2771335A2 (en) 2014-09-03
CR20140185A (es) 2014-06-03
NI201400031A (es) 2014-10-01
UA109220C2 (uk) 2015-07-27
CL2014000956A1 (es) 2014-07-18
ECSP14013324A (es) 2014-05-31
AU2012328034B2 (en) 2015-04-23
US9079878B2 (en) 2015-07-14
AP2014007579A0 (en) 2014-04-30
IL232267A0 (en) 2014-06-30
CN103906746B (zh) 2015-12-09
KR20140069234A (ko) 2014-06-09
TN2014000147A1 (fr) 2015-09-30
EA023375B1 (ru) 2016-05-31
CA2850925C (en) 2017-01-10
MX2014004738A (es) 2014-08-01
GT201400079A (es) 2015-06-02
WO2013061205A2 (en) 2013-05-02
AU2012328034A1 (en) 2014-05-15
HK1198650A1 (en) 2015-05-22
KR101586966B1 (ko) 2016-01-19
JP5946538B2 (ja) 2016-07-06
US20140296313A1 (en) 2014-10-02
EA201490864A1 (ru) 2014-08-29
BR112014009102A2 (pt) 2017-04-18
CU20140046A7 (es) 2014-10-02
ZA201402281B (en) 2015-11-25
MD20140037A2 (ro) 2014-08-31
IL232267A (en) 2016-10-31
CN103906746A (zh) 2014-07-02
JP2014530900A (ja) 2014-11-20
SG11201401032YA (en) 2014-07-30
PH12014500919A1 (en) 2014-06-09
WO2013061205A8 (en) 2014-03-27
MX337469B (es) 2016-03-02
NZ623090A (en) 2015-10-30
CO6940427A2 (es) 2014-05-09
CA2850925A1 (en) 2013-05-02
DOP2014000085A (es) 2014-08-31

Similar Documents

Publication Publication Date Title
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
PE20160432A1 (es) Compuestos utiles como inmunomoduladores
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20160608A1 (es) Compuestos de quinolina selectivamente sustituida
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20180177A1 (es) Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20181289A1 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PE20120812A1 (es) Compuestos vinil indazolilo
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
ECSP11011427A (es) Piperidinas sustituidas como antagonistas de ccr3.
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20142186A1 (es) Derivados biciclicos de pirazinona
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20140934A1 (es) Derivados de pirazol
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos

Legal Events

Date Code Title Description
FD Application declared void or lapsed